Investigation of the effects of systems in the treatment of brain damage in brain targeted liposomal carrier mice with rosuvastatin

Liposomes are one of the best delivery systems for biological membranes because they are similar to the cell structure and they can easily pass the active pharmaceutical ingredients through the membranes. In recent studies, it has been determined that Rosuvastatin (RSV) which is used as cholesterol lowering, has also been shown to have a neuroprotective effect after cerebral palsy. It has neuroprotective effect after cerebral palsy. Due to the hydrophilic structure of RSV, and due to the low permeability of the blood brain barrier, it has been envisaged that the surface modified liposomal delivery systems with appropriate particle size and distribution will increase the accessibility and efficiency effectiveness of RSV to the target tissue. Although traumatic brain injury is the most common cause of death and disability especially in the young age population, studies on pathophysiology and treatment are not yet sufficient. In this context, a protective drug has not yet been developed in the clinic for the treatment of neurodegenerative diseases in the clinic. In the scope of the thesis, the effect of RSV on damage and neuroinflammation caused by after brain trauma in mice was investigated. The surface of the RSV-loaded liposomes developed within the scope of the study was modified with a hydrophilic PEG and a specific ligand specific to the VCAM-1 expressed in the damaged area, making it suitable for targeting to the brain. The efficacy of intravenous liposomes was investigated in comparison with conventional treatment applications in brain-traumatized mice. As a result of the preliminary studies, the particle size of the optimized L2 formulation was 95.5 nm ± 0.44, the polydispersity index was 0.160 ± 0.001, the zeta potential was 33.2 mV ± 0.12 and the encapsulation capacity was 23.2 ± 0.12%. The fluorescence substance (calcein) loaded liposome formulation prepared with the L2 formulation showed higher accumulation in the brain-damaged region of the liposome formulation without targeting peptide. Targeted RSV loaded liposomal formulation showed a significant reduction in brain damage sites and edema levels after 24 hours.